Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)
1/2期
提前终止
NCT03869190
| 适应症 | Urothelial Carcinoma, Bladder Cancer |
|---|
| 分期 | 1/2期 |
|---|
| 申办方 | Hoffmann-La Roche |
|---|
| 状态 | 提前终止 |
|---|
| 受试者人数 | 272 人 |
|---|
| 干预（药物） | Atezolizumab, Enfortumab Vedotin, Niraparib, Magrolimab (Hu5F9-G4), Tiragolumab |
|---|
| 开始日期 | 2019年6月1日 |
|---|
| 完成日期 | 2025年10月8日 |
|---|
| 结果公布日 | 2026年8月3日 |
|---|
摘要
A Phase Ib/II, open-label, multicenter, randomized, umbrella study in participants with MIBC and in participants with locally advanced or metastatic Urothelial Carcinoma (UC) who have progressed during or following a platinum-containing regimen. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, or modify the participant population (e.g., with regard to prior anti-cancer treatment or biomarker status). Participants in the mUC Cohort who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to continue treatment with a different treatment regimen for Stage 2.
Stage 1 mUC Cohorts: Objective Response Rate (ORR)
Up to 61.5 months · percentage of participants
| Stage 1 mUC Cohort: Atezo (Control) | 27.6 percentage of participants |
|---|
| Stage 1 mUC Cohort: Atezo + EV | 26.7 percentage of participants |
|---|
| Stage 1 mUC Cohort: Atezo + Hu5F9-G4 | 26.7 percentage of participants |
|---|
| Stage 1 mUC Cohort: Atezo + Nira | 6.7 percentage of participants |
|---|
| Stage 1 mUC Cohort: Atezo + RO7122290 | 16.7 percentage of participants |
|---|
| Stage 1 mUC Cohort: Atezo + SG | 6.7 percentage of participants |
|---|
| Difference in Overall Response Rates | -0.92 (95% CI -33.64–31.80) |
|---|
MIBC Cohorts: Pathological Complete Response (pCR)
Up to 17.8 months · percentage of participants
| Stage 1 MIBC Cohort 1: Atezo (Control) | 66.7 percentage of participants |
|---|
| Stage 1 MIBC Cohort 1: Atezo + Tira | 27.3 percentage of participants |
|---|
| Stage 1 MIBC Cohort 2: Atezo (Control) | 21.7 percentage of participants |
|---|
| Stage 1 MIBC Cohort 2: Atezo + Tira | 20.0 percentage of participants |
|---|
| Stage 1 MIBC Cohort 3: Gem + Atezo + Cis (Control) | 27.8 percentage of participants |
|---|
| Stage 1 MIBC Cohort 3: Gem + Atezo + Cis + Tira | 23.5 percentage of participants |
|---|
| Difference in pCR Rates | -39.39 (95% CI -98.27–19.48) |
|---|
在 BENITIONS 中查看
查看 ClinicalTrials.gov 原文
全部试验
本页整理自 ClinicalTrials.gov 的公开数据，不构成医疗建议，也不构成投资建议。请务必咨询专业医师。